Sarepta Therapeutics (SRPT) Rating Reiterated by Leerink Swann

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “outperform” rating reaffirmed by Leerink Swann in a report released on Friday, The Fly reports. They currently have a $77.00 price objective on the biotechnology company’s stock. Leerink Swann’s target price indicates a potential upside of 23.44% from the company’s current price. Leerink Swann also issued estimates for Sarepta Therapeutics’ FY2020 earnings at $2.91 EPS.

Several other equities research analysts have also issued reports on the company. Zacks Investment Research raised Sarepta Therapeutics from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a research note on Monday, October 30th. Oppenheimer reaffirmed a “buy” rating and issued a $76.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 16th. HC Wainwright initiated coverage on Sarepta Therapeutics in a research note on Friday, December 1st. They issued a “buy” rating and a $75.00 price objective for the company. Goldman Sachs Group reaffirmed a “buy” rating and issued a $71.00 price objective on shares of Sarepta Therapeutics in a research note on Friday, October 6th. Finally, UBS Group reaffirmed an “outperform” rating and issued a $56.51 price objective (down from $76.00) on shares of Sarepta Therapeutics in a research note on Wednesday, December 27th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and eighteen have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $64.38.

Sarepta Therapeutics (SRPT) traded up $0.54 during trading hours on Friday, hitting $62.38. The stock had a trading volume of 1,227,480 shares, compared to its average volume of 1,720,000. The company has a market cap of $4,070.00, a price-to-earnings ratio of -30.58 and a beta of 1.37. Sarepta Therapeutics has a 1-year low of $26.26 and a 1-year high of $62.96. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.66. The business had revenue of $45.95 million during the quarter, compared to analyst estimates of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same period last year, the company earned ($0.95) EPS. analysts expect that Sarepta Therapeutics will post -3.07 earnings per share for the current year.

In related news, SVP Shamim Ruff sold 10,000 shares of the business’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $55.00, for a total transaction of $550,000.00. Following the transaction, the senior vice president now directly owns 37,045 shares in the company, valued at approximately $2,037,475. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the business’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $55.89, for a total value of $372,618.63. Following the transaction, the director now owns 13,333 shares in the company, valued at $745,181.37. The disclosure for this sale can be found here. Company insiders own 9.60% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in Sarepta Therapeutics by 4.0% during the 2nd quarter. Vanguard Group Inc. now owns 4,259,029 shares of the biotechnology company’s stock worth $143,572,000 after acquiring an additional 162,543 shares during the period. HealthCor Management L.P. lifted its position in Sarepta Therapeutics by 31.1% during the 2nd quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock worth $68,495,000 after acquiring an additional 481,890 shares during the period. Jennison Associates LLC lifted its position in Sarepta Therapeutics by 103.9% during the 3rd quarter. Jennison Associates LLC now owns 1,143,853 shares of the biotechnology company’s stock worth $51,885,000 after acquiring an additional 582,894 shares during the period. Eagle Asset Management Inc. lifted its position in Sarepta Therapeutics by 26.0% during the 3rd quarter. Eagle Asset Management Inc. now owns 1,006,222 shares of the biotechnology company’s stock worth $49,858,000 after acquiring an additional 207,810 shares during the period. Finally, Emerald Advisers Inc. PA lifted its position in Sarepta Therapeutics by 2.1% during the 3rd quarter. Emerald Advisers Inc. PA now owns 893,484 shares of the biotechnology company’s stock worth $40,528,000 after acquiring an additional 18,077 shares during the period. Hedge funds and other institutional investors own 82.02% of the company’s stock.

WARNING: “Sarepta Therapeutics (SRPT) Rating Reiterated by Leerink Swann” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/20/sarepta-therapeutics-srpt-rating-reiterated-by-leerink-swann.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

The Fly

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply